nodes	percent_of_prediction	percent_of_DWPC	metapath
Tretinoin—peripheral nervous system neoplasm—sarcoma	0.548	1	CtDrD
Tretinoin—NR0B1—Vincristine—sarcoma	0.155	0.535	CbGbCtD
Tretinoin—CYP2B6—Thiotepa—sarcoma	0.035	0.121	CbGbCtD
Tretinoin—CYP1A1—Dacarbazine—sarcoma	0.0255	0.0877	CbGbCtD
Tretinoin—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0109	0.0375	CbGbCtD
Tretinoin—CYP3A7—Vincristine—sarcoma	0.0109	0.0375	CbGbCtD
Tretinoin—CYP3A4—Thiotepa—sarcoma	0.0108	0.037	CbGbCtD
Tretinoin—CYP3A5—Vincristine—sarcoma	0.00817	0.0281	CbGbCtD
Tretinoin—CYP3A5—Etoposide—sarcoma	0.00748	0.0258	CbGbCtD
Tretinoin—CYP2C8—Etoposide—sarcoma	0.0072	0.0248	CbGbCtD
Tretinoin—CYP2B6—Doxorubicin—sarcoma	0.00648	0.0223	CbGbCtD
Tretinoin—CYP3A4—Mitoxantrone—sarcoma	0.00463	0.0159	CbGbCtD
Tretinoin—CYP3A4—Vincristine—sarcoma	0.00318	0.011	CbGbCtD
Tretinoin—CYP3A4—Etoposide—sarcoma	0.00292	0.01	CbGbCtD
Tretinoin—CYP3A4—Doxorubicin—sarcoma	0.00199	0.00685	CbGbCtD
Tretinoin—NR0B1—Validated nuclear estrogen receptor beta network—SMARCB1—sarcoma	0.00196	0.128	CbGpPWpGaD
Tretinoin—RARRES1—mammary gland—sarcoma	0.00178	0.0394	CbGeAlD
Tretinoin—RARRES1—myometrium—sarcoma	0.00126	0.028	CbGeAlD
Tretinoin—RARRES1—seminal vesicle—sarcoma	0.00114	0.0253	CbGeAlD
Tretinoin—ALDH1A1—mammary gland—sarcoma	0.000991	0.022	CbGeAlD
Tretinoin—ALDH1A1—Folate-Alcohol and Cancer Pathway—CREB1—sarcoma	0.00097	0.0635	CbGpPWpGaD
Tretinoin—RARRES1—skin of body—sarcoma	0.000941	0.0209	CbGeAlD
Tretinoin—ALDH1A2—embryo—sarcoma	0.00093	0.0207	CbGeAlD
Tretinoin—CRABP1—embryo—sarcoma	0.000898	0.0199	CbGeAlD
Tretinoin—CRABP2—myometrium—sarcoma	0.000844	0.0187	CbGeAlD
Tretinoin—ALDH1A2—hematopoietic system—sarcoma	0.00083	0.0184	CbGeAlD
Tretinoin—RARRES1—cardiac atrium—sarcoma	0.000822	0.0182	CbGeAlD
Tretinoin—RARRES1—uterus—sarcoma	0.000818	0.0182	CbGeAlD
Tretinoin—RARA—mammary gland—sarcoma	0.000816	0.0181	CbGeAlD
Tretinoin—CRABP2—embryo—sarcoma	0.000812	0.018	CbGeAlD
Tretinoin—CRABP1—hematopoietic system—sarcoma	0.000801	0.0178	CbGeAlD
Tretinoin—CRABP1—connective tissue—sarcoma	0.000771	0.0171	CbGeAlD
Tretinoin—CRABP2—seminal vesicle—sarcoma	0.000762	0.0169	CbGeAlD
Tretinoin—ALDH1A1—Teniposide—Etoposide—sarcoma	0.000751	0.271	CbGdCrCtD
Tretinoin—ALDH1A1—Podofilox—Etoposide—sarcoma	0.000751	0.271	CbGdCrCtD
Tretinoin—RARRES1—tendon—sarcoma	0.000716	0.0159	CbGeAlD
Tretinoin—ALDH1A1—myometrium—sarcoma	0.000703	0.0156	CbGeAlD
Tretinoin—CRABP2—connective tissue—sarcoma	0.000698	0.0155	CbGeAlD
Tretinoin—CRABP1—skin of body—sarcoma	0.000697	0.0155	CbGeAlD
Tretinoin—ALDH1A1—embryo—sarcoma	0.000676	0.015	CbGeAlD
Tretinoin—CRABP2—smooth muscle tissue—sarcoma	0.000638	0.0142	CbGeAlD
Tretinoin—ALDH1A1—seminal vesicle—sarcoma	0.000635	0.0141	CbGeAlD
Tretinoin—CRABP2—skin of body—sarcoma	0.00063	0.014	CbGeAlD
Tretinoin—ALDH1A2—uterus—sarcoma	0.000627	0.0139	CbGeAlD
Tretinoin—ALDH1A1—hematopoietic system—sarcoma	0.000604	0.0134	CbGeAlD
Tretinoin—RARRES1—testis—sarcoma	0.000593	0.0132	CbGeAlD
Tretinoin—ALDH1A1—connective tissue—sarcoma	0.000581	0.0129	CbGeAlD
Tretinoin—RARA—myometrium—sarcoma	0.000579	0.0129	CbGeAlD
Tretinoin—NR0B1—Validated nuclear estrogen receptor alpha network—COL18A1—sarcoma	0.000552	0.0362	CbGpPWpGaD
Tretinoin—ALDH1A1—smooth muscle tissue—sarcoma	0.000532	0.0118	CbGeAlD
Tretinoin—CRABP1—tendon—sarcoma	0.00053	0.0118	CbGeAlD
Tretinoin—RARG—hematopoietic system—sarcoma	0.000529	0.0117	CbGeAlD
Tretinoin—ALDH1A1—skin of body—sarcoma	0.000525	0.0117	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000518	0.0339	CbGpPWpGaD
Tretinoin—ALDH1A1—Vinblastine—Vincristine—sarcoma	0.000517	0.186	CbGdCrCtD
Tretinoin—NR0B1—testis—sarcoma	0.000511	0.0113	CbGeAlD
Tretinoin—RARA—hematopoietic system—sarcoma	0.000497	0.011	CbGeAlD
Tretinoin—CRABP2—tendon—sarcoma	0.00048	0.0106	CbGeAlD
Tretinoin—RARG—skin of body—sarcoma	0.00046	0.0102	CbGeAlD
Tretinoin—ALDH1A1—cardiac atrium—sarcoma	0.000458	0.0102	CbGeAlD
Tretinoin—ALDH1A1—uterus—sarcoma	0.000456	0.0101	CbGeAlD
Tretinoin—ALDH1A2—testis—sarcoma	0.000455	0.0101	CbGeAlD
Tretinoin—RXRB—cardiac atrium—sarcoma	0.000452	0.01	CbGeAlD
Tretinoin—CRABP1—testis—sarcoma	0.000439	0.00975	CbGeAlD
Tretinoin—ALDH1A2—liver—sarcoma	0.00043	0.00955	CbGeAlD
Tretinoin—RARRES1—lymph node—sarcoma	0.00043	0.00955	CbGeAlD
Tretinoin—RARB—tendon—sarcoma	0.000429	0.00952	CbGeAlD
Tretinoin—ALDH1A1—lymphoid tissue—sarcoma	0.000425	0.00944	CbGeAlD
Tretinoin—RXRG—tendon—sarcoma	0.000419	0.00931	CbGeAlD
Tretinoin—CYP4A11—liver—sarcoma	0.000415	0.00922	CbGeAlD
Tretinoin—ALDH1A1—tendon—sarcoma	0.0004	0.00887	CbGeAlD
Tretinoin—RARG—uterus—sarcoma	0.000399	0.00886	CbGeAlD
Tretinoin—ALDH1A2—Tryptophan metabolism—MDM2—sarcoma	0.000397	0.026	CbGpPWpGaD
Tretinoin—CRABP2—testis—sarcoma	0.000397	0.00882	CbGeAlD
Tretinoin—RXRB—tendon—sarcoma	0.000394	0.00875	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Epirubicin—sarcoma	0.000392	0.141	CbGdCrCtD
Tretinoin—ALDH1A1—bone marrow—sarcoma	0.000387	0.00859	CbGeAlD
Tretinoin—RARA—uterus—sarcoma	0.000375	0.00833	CbGeAlD
Tretinoin—RXRA—liver—sarcoma	0.000374	0.0083	CbGeAlD
Tretinoin—CYP2A6—seminal vesicle—sarcoma	0.000369	0.00819	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Doxorubicin—sarcoma	0.000362	0.131	CbGdCrCtD
Tretinoin—RARA—lymphoid tissue—sarcoma	0.00035	0.00777	CbGeAlD
Tretinoin—RARG—tendon—sarcoma	0.00035	0.00777	CbGeAlD
Tretinoin—RXRG—testis—sarcoma	0.000347	0.00771	CbGeAlD
Tretinoin—RARB—liver—sarcoma	0.000336	0.00745	CbGeAlD
Tretinoin—ALDH1A1—testis—sarcoma	0.000331	0.00735	CbGeAlD
Tretinoin—ALDH1A2—lymph node—sarcoma	0.00033	0.00732	CbGeAlD
Tretinoin—RARA—tendon—sarcoma	0.000329	0.0073	CbGeAlD
Tretinoin—RXRB—testis—sarcoma	0.000326	0.00724	CbGeAlD
Tretinoin—CYP2C8—mammary gland—sarcoma	0.000323	0.00717	CbGeAlD
Tretinoin—RARA—bone marrow—sarcoma	0.000319	0.00707	CbGeAlD
Tretinoin—ALDH1A1—liver—sarcoma	0.000313	0.00694	CbGeAlD
Tretinoin—RXRB—liver—sarcoma	0.000309	0.00685	CbGeAlD
Tretinoin—CYP2C18—FOXA1 transcription factor network—COL18A1—sarcoma	0.000297	0.0194	CbGpPWpGaD
Tretinoin—RARG—testis—sarcoma	0.00029	0.00643	CbGeAlD
Tretinoin—CYP2C9—mammary gland—sarcoma	0.000287	0.00637	CbGeAlD
Tretinoin—CYP2C18—liver—sarcoma	0.000275	0.0061	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000275	0.018	CbGpPWpGaD
Tretinoin—RARA—testis—sarcoma	0.000272	0.00605	CbGeAlD
Tretinoin—NR0B1—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.000271	0.0178	CbGpPWpGaD
Tretinoin—CYP3A7—liver—sarcoma	0.000262	0.00581	CbGeAlD
Tretinoin—RARA—liver—sarcoma	0.000257	0.00572	CbGeAlD
Tretinoin—RARB—lymph node—sarcoma	0.000257	0.00571	CbGeAlD
Tretinoin—ALDH1A1—lymph node—sarcoma	0.00024	0.00532	CbGeAlD
Tretinoin—CYP3A7-CYP3A51P—liver—sarcoma	0.000222	0.00494	CbGeAlD
Tretinoin—ALDH1A1—Tryptophan metabolism—MDM2—sarcoma	0.000218	0.0143	CbGpPWpGaD
Tretinoin—RARG—lymph node—sarcoma	0.00021	0.00466	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000203	0.0133	CbGpPWpGaD
Tretinoin—RXRG—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.0002	0.0131	CbGpPWpGaD
Tretinoin—RXRA—Transcription factor regulation in adipogenesis—FOXO1—sarcoma	0.000198	0.013	CbGpPWpGaD
Tretinoin—RARA—lymph node—sarcoma	0.000197	0.00438	CbGeAlD
Tretinoin—CYP2C8—hematopoietic system—sarcoma	0.000197	0.00437	CbGeAlD
Tretinoin—RXRB—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.000188	0.0123	CbGpPWpGaD
Tretinoin—CYP4A11—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000185	0.0121	CbGpPWpGaD
Tretinoin—CYP1A1—hematopoietic system—sarcoma	0.000182	0.00404	CbGeAlD
Tretinoin—CYP2A6—liver—sarcoma	0.000182	0.00403	CbGeAlD
Tretinoin—CYP3A5—hematopoietic system—sarcoma	0.000178	0.00395	CbGeAlD
Tretinoin—CYP2B6—hematopoietic system—sarcoma	0.000177	0.00392	CbGeAlD
Tretinoin—CYP2C9—hematopoietic system—sarcoma	0.000175	0.00388	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000168	0.011	CbGpPWpGaD
Tretinoin—NR0B1—Regulation of Androgen receptor activity—MDM2—sarcoma	0.000163	0.0107	CbGpPWpGaD
Tretinoin—CYP1A1—skin of body—sarcoma	0.000158	0.00351	CbGeAlD
Tretinoin—CYP2B6—skin of body—sarcoma	0.000154	0.00341	CbGeAlD
Tretinoin—RXRA—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000147	0.00961	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000146	0.00957	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000146	0.00955	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000145	0.00948	CbGpPWpGaD
Tretinoin—RXRA—Transcription factor regulation in adipogenesis—CREB1—sarcoma	0.000144	0.00941	CbGpPWpGaD
Tretinoin—NR0B1—Regulation of Androgen receptor activity—JUN—sarcoma	0.000142	0.00927	CbGpPWpGaD
Tretinoin—CYP1A1—cardiac atrium—sarcoma	0.000138	0.00306	CbGeAlD
Tretinoin—CYP1A1—uterus—sarcoma	0.000137	0.00305	CbGeAlD
Tretinoin—CYP3A4—hematopoietic system—sarcoma	0.000133	0.00296	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000131	0.00857	CbGpPWpGaD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.00013	0.00853	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000127	0.00835	CbGpPWpGaD
Tretinoin—NR0B1—Regulation of Androgen receptor activity—SRC—sarcoma	0.000127	0.00832	CbGpPWpGaD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000125	0.00818	CbGpPWpGaD
Tretinoin—CYP2A6—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000125	0.00817	CbGpPWpGaD
Tretinoin—CYP2B6—lymphoid tissue—sarcoma	0.000124	0.00276	CbGeAlD
Tretinoin—NR0B1—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	0.000122	0.00799	CbGpPWpGaD
Tretinoin—NR0B1—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	0.000122	0.00797	CbGpPWpGaD
Tretinoin—RXRG—Regulation of Androgen receptor activity—MDM2—sarcoma	0.00012	0.00786	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000117	0.00768	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000115	0.00751	CbGpPWpGaD
Tretinoin—CYP4A11—PPAR Alpha Pathway—CCND1—sarcoma	0.000114	0.00748	CbGpPWpGaD
Tretinoin—RXRB—Regulation of Androgen receptor activity—MDM2—sarcoma	0.000113	0.00739	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000108	0.0071	CbGpPWpGaD
Tretinoin—CYP2C8—testis—sarcoma	0.000108	0.0024	CbGeAlD
Tretinoin—RXRG—Regulation of Androgen receptor activity—JUN—sarcoma	0.000104	0.00684	CbGpPWpGaD
Tretinoin—CYP2C8—liver—sarcoma	0.000102	0.00226	CbGeAlD
Tretinoin—CYP2A6—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	9.86e-05	0.00646	CbGpPWpGaD
Tretinoin—RXRB—Regulation of Androgen receptor activity—JUN—sarcoma	9.81e-05	0.00643	CbGpPWpGaD
Tretinoin—RXRA—Regulation of Androgen receptor activity—FOXO1—sarcoma	9.8e-05	0.00642	CbGpPWpGaD
Tretinoin—NR0B1—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	9.78e-05	0.00641	CbGpPWpGaD
Tretinoin—RXRG—Adipogenesis—FOXO1—sarcoma	9.76e-05	0.00639	CbGpPWpGaD
Tretinoin—CYP2B6—testis—sarcoma	9.68e-05	0.00215	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	9.63e-05	0.00631	CbGpPWpGaD
Tretinoin—CYP1A1—liver—sarcoma	9.42e-05	0.00209	CbGeAlD
Tretinoin—RXRG—Regulation of Androgen receptor activity—SRC—sarcoma	9.36e-05	0.00613	CbGpPWpGaD
Tretinoin—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—sarcoma	9.35e-05	0.00613	CbGpPWpGaD
Tretinoin—CYP3A5—liver—sarcoma	9.21e-05	0.00204	CbGeAlD
Tretinoin—RARA—Adipogenesis—FOXO1—sarcoma	9.18e-05	0.00601	CbGpPWpGaD
Tretinoin—CYP4A11—PPAR Alpha Pathway—MYC—sarcoma	9.16e-05	0.006	CbGpPWpGaD
Tretinoin—CYP2B6—liver—sarcoma	9.15e-05	0.00203	CbGeAlD
Tretinoin—CYP2C9—liver—sarcoma	9.06e-05	0.00201	CbGeAlD
Tretinoin—RXRA—PPAR Alpha Pathway—CCND1—sarcoma	9.06e-05	0.00593	CbGpPWpGaD
Tretinoin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	8.95e-05	0.00586	CbGpPWpGaD
Tretinoin—RXRB—Regulation of Androgen receptor activity—SRC—sarcoma	8.8e-05	0.00576	CbGpPWpGaD
Tretinoin—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—sarcoma	8.79e-05	0.00576	CbGpPWpGaD
Tretinoin—RXRA—Transcriptional activation of mitochondrial biogenesis—CREB1—sarcoma	8.1e-05	0.00531	CbGpPWpGaD
Tretinoin—CYP2B6—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.95e-05	0.00521	CbGpPWpGaD
Tretinoin—CYP1A1—Melatonin metabolism and effects—FOXO1—sarcoma	7.94e-05	0.0052	CbGpPWpGaD
Tretinoin—CYP1A1—Estrogen Receptor Pathway—JUN—sarcoma	7.87e-05	0.00516	CbGpPWpGaD
Tretinoin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	7.82e-05	0.00512	CbGpPWpGaD
Tretinoin—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	7.77e-05	0.00509	CbGpPWpGaD
Tretinoin—RXRG—a6b1 and a6b4 Integrin signaling—HRAS—sarcoma	7.51e-05	0.00492	CbGpPWpGaD
Tretinoin—NR0B1—Gene Expression—FUS—sarcoma	7.5e-05	0.00491	CbGpPWpGaD
Tretinoin—RXRA—PPAR Alpha Pathway—MYC—sarcoma	7.27e-05	0.00476	CbGpPWpGaD
Tretinoin—CYP2C18—Tryptophan metabolism—MDM2—sarcoma	7.26e-05	0.00476	CbGpPWpGaD
Tretinoin—CYP1A1—lymph node—sarcoma	7.22e-05	0.0016	CbGeAlD
Tretinoin—RXRG—Adipogenesis—CREB1—sarcoma	7.08e-05	0.00464	CbGpPWpGaD
Tretinoin—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—sarcoma	7.06e-05	0.00462	CbGpPWpGaD
Tretinoin—RXRA—Mitochondrial biogenesis—CREB1—sarcoma	7e-05	0.00459	CbGpPWpGaD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	6.91e-05	0.00453	CbGpPWpGaD
Tretinoin—CYP3A4—liver—sarcoma	6.91e-05	0.00153	CbGeAlD
Tretinoin—RXRA—Circadian Clock—CREB1—sarcoma	6.9e-05	0.00452	CbGpPWpGaD
Tretinoin—RARA—Adipogenesis—CREB1—sarcoma	6.65e-05	0.00436	CbGpPWpGaD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	6.63e-05	0.00434	CbGpPWpGaD
Tretinoin—CYP2C18—FOXA1 transcription factor network—JUN—sarcoma	6.54e-05	0.00428	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	6.51e-05	0.00426	CbGpPWpGaD
Tretinoin—RARG—Gene Expression—FUS—sarcoma	6.05e-05	0.00396	CbGpPWpGaD
Tretinoin—RXRA—Regulation of Androgen receptor activity—MDM2—sarcoma	5.88e-05	0.00385	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—FUS—sarcoma	5.53e-05	0.00362	CbGpPWpGaD
Tretinoin—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	5.48e-05	0.00359	CbGpPWpGaD
Tretinoin—RARB—Gene Expression—FUS—sarcoma	5.42e-05	0.00355	CbGpPWpGaD
Tretinoin—Pollakiuria—Epirubicin—sarcoma	5.41e-05	0.00055	CcSEcCtD
Tretinoin—Hypersensitivity—Vincristine—sarcoma	5.4e-05	0.000549	CcSEcCtD
Tretinoin—Photosensitivity reaction—Epirubicin—sarcoma	5.34e-05	0.000543	CcSEcCtD
Tretinoin—Paraesthesia—Etoposide—sarcoma	5.33e-05	0.000542	CcSEcCtD
Tretinoin—Weight increased—Epirubicin—sarcoma	5.33e-05	0.000541	CcSEcCtD
Tretinoin—Pancreatitis—Doxorubicin—sarcoma	5.31e-05	0.00054	CcSEcCtD
Tretinoin—RXRA—Developmental Biology—MYOG—sarcoma	5.3e-05	0.00347	CbGpPWpGaD
Tretinoin—Weight decreased—Epirubicin—sarcoma	5.29e-05	0.000538	CcSEcCtD
Tretinoin—Dyspnoea—Etoposide—sarcoma	5.29e-05	0.000538	CcSEcCtD
Tretinoin—Somnolence—Etoposide—sarcoma	5.28e-05	0.000537	CcSEcCtD
Tretinoin—Hypersensitivity—Mitoxantrone—sarcoma	5.26e-05	0.000535	CcSEcCtD
Tretinoin—Asthenia—Vincristine—sarcoma	5.26e-05	0.000535	CcSEcCtD
Tretinoin—Vomiting—Thiotepa—sarcoma	5.26e-05	0.000534	CcSEcCtD
Tretinoin—Pneumonia—Epirubicin—sarcoma	5.25e-05	0.000534	CcSEcCtD
Tretinoin—Drowsiness—Epirubicin—sarcoma	5.22e-05	0.000531	CcSEcCtD
Tretinoin—Infestation NOS—Epirubicin—sarcoma	5.22e-05	0.000531	CcSEcCtD
Tretinoin—Infestation—Epirubicin—sarcoma	5.22e-05	0.000531	CcSEcCtD
Tretinoin—Vomiting—Dactinomycin—sarcoma	5.22e-05	0.00053	CcSEcCtD
Tretinoin—Rash—Thiotepa—sarcoma	5.21e-05	0.00053	CcSEcCtD
Tretinoin—Dermatitis—Thiotepa—sarcoma	5.21e-05	0.000529	CcSEcCtD
Tretinoin—RXRB—Gene Expression—FUS—sarcoma	5.2e-05	0.00341	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—FUS—sarcoma	5.2e-05	0.00341	CbGpPWpGaD
Tretinoin—Headache—Thiotepa—sarcoma	5.18e-05	0.000526	CcSEcCtD
Tretinoin—Stevens-Johnson syndrome—Epirubicin—sarcoma	5.17e-05	0.000526	CcSEcCtD
Tretinoin—Rash—Dactinomycin—sarcoma	5.17e-05	0.000526	CcSEcCtD
Tretinoin—Decreased appetite—Etoposide—sarcoma	5.16e-05	0.000525	CcSEcCtD
Tretinoin—Renal failure—Epirubicin—sarcoma	5.13e-05	0.000521	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Etoposide—sarcoma	5.13e-05	0.000521	CcSEcCtD
Tretinoin—Asthenia—Mitoxantrone—sarcoma	5.12e-05	0.000521	CcSEcCtD
Tretinoin—Fatigue—Etoposide—sarcoma	5.12e-05	0.00052	CcSEcCtD
Tretinoin—Neuropathy peripheral—Epirubicin—sarcoma	5.11e-05	0.00052	CcSEcCtD
Tretinoin—RXRA—Regulation of Androgen receptor activity—JUN—sarcoma	5.11e-05	0.00335	CbGpPWpGaD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	5.1e-05	0.00334	CbGpPWpGaD
Tretinoin—Stomatitis—Epirubicin—sarcoma	5.09e-05	0.000517	CcSEcCtD
Tretinoin—Constipation—Etoposide—sarcoma	5.08e-05	0.000516	CcSEcCtD
Tretinoin—Pain—Etoposide—sarcoma	5.08e-05	0.000516	CcSEcCtD
Tretinoin—Urinary tract infection—Epirubicin—sarcoma	5.07e-05	0.000516	CcSEcCtD
Tretinoin—Conjunctivitis—Epirubicin—sarcoma	5.07e-05	0.000516	CcSEcCtD
Tretinoin—Dysuria—Doxorubicin—sarcoma	5.06e-05	0.000515	CcSEcCtD
Tretinoin—Neutropenia—Doxorubicin—sarcoma	5.06e-05	0.000515	CcSEcCtD
Tretinoin—RXRG—Adipogenesis—CTNNB1—sarcoma	5.05e-05	0.00331	CbGpPWpGaD
Tretinoin—Upper respiratory tract infection—Doxorubicin—sarcoma	5.03e-05	0.000512	CcSEcCtD
Tretinoin—Diarrhoea—Vincristine—sarcoma	5.01e-05	0.00051	CcSEcCtD
Tretinoin—Sweating—Epirubicin—sarcoma	5e-05	0.000509	CcSEcCtD
Tretinoin—Pollakiuria—Doxorubicin—sarcoma	5e-05	0.000509	CcSEcCtD
Tretinoin—Haematuria—Epirubicin—sarcoma	4.98e-05	0.000506	CcSEcCtD
Tretinoin—Photosensitivity reaction—Doxorubicin—sarcoma	4.94e-05	0.000503	CcSEcCtD
Tretinoin—Weight increased—Doxorubicin—sarcoma	4.93e-05	0.000501	CcSEcCtD
Tretinoin—Epistaxis—Epirubicin—sarcoma	4.92e-05	0.0005	CcSEcCtD
Tretinoin—Nausea—Thiotepa—sarcoma	4.91e-05	0.000499	CcSEcCtD
Tretinoin—Weight decreased—Doxorubicin—sarcoma	4.9e-05	0.000498	CcSEcCtD
Tretinoin—Sinusitis—Epirubicin—sarcoma	4.9e-05	0.000498	CcSEcCtD
Tretinoin—Feeling abnormal—Etoposide—sarcoma	4.89e-05	0.000497	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	4.89e-05	0.0032	CbGpPWpGaD
Tretinoin—Diarrhoea—Mitoxantrone—sarcoma	4.88e-05	0.000497	CcSEcCtD
Tretinoin—Nausea—Dactinomycin—sarcoma	4.87e-05	0.000495	CcSEcCtD
Tretinoin—Agranulocytosis—Epirubicin—sarcoma	4.87e-05	0.000495	CcSEcCtD
Tretinoin—Pneumonia—Doxorubicin—sarcoma	4.86e-05	0.000494	CcSEcCtD
Tretinoin—Gastrointestinal pain—Etoposide—sarcoma	4.85e-05	0.000494	CcSEcCtD
Tretinoin—Dizziness—Vincristine—sarcoma	4.85e-05	0.000493	CcSEcCtD
Tretinoin—Infestation NOS—Doxorubicin—sarcoma	4.83e-05	0.000491	CcSEcCtD
Tretinoin—Drowsiness—Doxorubicin—sarcoma	4.83e-05	0.000491	CcSEcCtD
Tretinoin—Infestation—Doxorubicin—sarcoma	4.83e-05	0.000491	CcSEcCtD
Tretinoin—Stevens-Johnson syndrome—Doxorubicin—sarcoma	4.79e-05	0.000487	CcSEcCtD
Tretinoin—RXRA—Adipogenesis—FOXO1—sarcoma	4.78e-05	0.00313	CbGpPWpGaD
Tretinoin—RARA—Adipogenesis—CTNNB1—sarcoma	4.75e-05	0.00311	CbGpPWpGaD
Tretinoin—Renal failure—Doxorubicin—sarcoma	4.75e-05	0.000483	CcSEcCtD
Tretinoin—Neuropathy peripheral—Doxorubicin—sarcoma	4.73e-05	0.000481	CcSEcCtD
Tretinoin—Urticaria—Etoposide—sarcoma	4.72e-05	0.00048	CcSEcCtD
Tretinoin—Haemoglobin—Epirubicin—sarcoma	4.71e-05	0.000479	CcSEcCtD
Tretinoin—Stomatitis—Doxorubicin—sarcoma	4.71e-05	0.000478	CcSEcCtD
Tretinoin—Body temperature increased—Etoposide—sarcoma	4.69e-05	0.000477	CcSEcCtD
Tretinoin—Abdominal pain—Etoposide—sarcoma	4.69e-05	0.000477	CcSEcCtD
Tretinoin—Urinary tract infection—Doxorubicin—sarcoma	4.69e-05	0.000477	CcSEcCtD
Tretinoin—Conjunctivitis—Doxorubicin—sarcoma	4.69e-05	0.000477	CcSEcCtD
Tretinoin—Hepatitis—Epirubicin—sarcoma	4.68e-05	0.000476	CcSEcCtD
Tretinoin—Haemorrhage—Epirubicin—sarcoma	4.68e-05	0.000476	CcSEcCtD
Tretinoin—Hypoaesthesia—Epirubicin—sarcoma	4.66e-05	0.000474	CcSEcCtD
Tretinoin—Vomiting—Vincristine—sarcoma	4.66e-05	0.000474	CcSEcCtD
Tretinoin—Pharyngitis—Epirubicin—sarcoma	4.65e-05	0.000473	CcSEcCtD
Tretinoin—Sweating—Doxorubicin—sarcoma	4.63e-05	0.000471	CcSEcCtD
Tretinoin—Urinary tract disorder—Epirubicin—sarcoma	4.63e-05	0.00047	CcSEcCtD
Tretinoin—Rash—Vincristine—sarcoma	4.62e-05	0.00047	CcSEcCtD
Tretinoin—Dermatitis—Vincristine—sarcoma	4.62e-05	0.000469	CcSEcCtD
Tretinoin—Oedema peripheral—Epirubicin—sarcoma	4.61e-05	0.000469	CcSEcCtD
Tretinoin—Haematuria—Doxorubicin—sarcoma	4.6e-05	0.000468	CcSEcCtD
Tretinoin—Urethral disorder—Epirubicin—sarcoma	4.59e-05	0.000467	CcSEcCtD
Tretinoin—Headache—Vincristine—sarcoma	4.59e-05	0.000467	CcSEcCtD
Tretinoin—RXRA—Regulation of Androgen receptor activity—SRC—sarcoma	4.59e-05	0.003	CbGpPWpGaD
Tretinoin—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—sarcoma	4.58e-05	0.003	CbGpPWpGaD
Tretinoin—Epistaxis—Doxorubicin—sarcoma	4.55e-05	0.000463	CcSEcCtD
Tretinoin—Vomiting—Mitoxantrone—sarcoma	4.54e-05	0.000461	CcSEcCtD
Tretinoin—Sinusitis—Doxorubicin—sarcoma	4.53e-05	0.000461	CcSEcCtD
Tretinoin—Visual impairment—Epirubicin—sarcoma	4.51e-05	0.000459	CcSEcCtD
Tretinoin—Agranulocytosis—Doxorubicin—sarcoma	4.51e-05	0.000458	CcSEcCtD
Tretinoin—Rash—Mitoxantrone—sarcoma	4.5e-05	0.000458	CcSEcCtD
Tretinoin—Dermatitis—Mitoxantrone—sarcoma	4.5e-05	0.000457	CcSEcCtD
Tretinoin—Headache—Mitoxantrone—sarcoma	4.47e-05	0.000455	CcSEcCtD
Tretinoin—Erythema multiforme—Epirubicin—sarcoma	4.43e-05	0.00045	CcSEcCtD
Tretinoin—Eye disorder—Epirubicin—sarcoma	4.38e-05	0.000445	CcSEcCtD
Tretinoin—Hypersensitivity—Etoposide—sarcoma	4.37e-05	0.000445	CcSEcCtD
Tretinoin—Tinnitus—Epirubicin—sarcoma	4.37e-05	0.000444	CcSEcCtD
Tretinoin—Haemoglobin—Doxorubicin—sarcoma	4.36e-05	0.000443	CcSEcCtD
Tretinoin—Nausea—Vincristine—sarcoma	4.35e-05	0.000443	CcSEcCtD
Tretinoin—Flushing—Epirubicin—sarcoma	4.35e-05	0.000442	CcSEcCtD
Tretinoin—Haemorrhage—Doxorubicin—sarcoma	4.33e-05	0.000441	CcSEcCtD
Tretinoin—Hepatitis—Doxorubicin—sarcoma	4.33e-05	0.000441	CcSEcCtD
Tretinoin—Hypoaesthesia—Doxorubicin—sarcoma	4.31e-05	0.000438	CcSEcCtD
Tretinoin—Pharyngitis—Doxorubicin—sarcoma	4.3e-05	0.000437	CcSEcCtD
Tretinoin—Urinary tract disorder—Doxorubicin—sarcoma	4.28e-05	0.000435	CcSEcCtD
Tretinoin—Oedema peripheral—Doxorubicin—sarcoma	4.27e-05	0.000434	CcSEcCtD
Tretinoin—Asthenia—Etoposide—sarcoma	4.26e-05	0.000433	CcSEcCtD
Tretinoin—Angiopathy—Epirubicin—sarcoma	4.25e-05	0.000432	CcSEcCtD
Tretinoin—Urethral disorder—Doxorubicin—sarcoma	4.25e-05	0.000432	CcSEcCtD
Tretinoin—Nausea—Mitoxantrone—sarcoma	4.24e-05	0.000431	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.22e-05	0.00277	CbGpPWpGaD
Tretinoin—Chills—Epirubicin—sarcoma	4.2e-05	0.000427	CcSEcCtD
Tretinoin—Pruritus—Etoposide—sarcoma	4.2e-05	0.000427	CcSEcCtD
Tretinoin—Arrhythmia—Epirubicin—sarcoma	4.18e-05	0.000425	CcSEcCtD
Tretinoin—Visual impairment—Doxorubicin—sarcoma	4.18e-05	0.000425	CcSEcCtD
Tretinoin—Alopecia—Epirubicin—sarcoma	4.14e-05	0.000421	CcSEcCtD
Tretinoin—Mental disorder—Epirubicin—sarcoma	4.1e-05	0.000417	CcSEcCtD
Tretinoin—Erythema multiforme—Doxorubicin—sarcoma	4.1e-05	0.000417	CcSEcCtD
Tretinoin—Malnutrition—Epirubicin—sarcoma	4.08e-05	0.000415	CcSEcCtD
Tretinoin—Erythema—Epirubicin—sarcoma	4.08e-05	0.000415	CcSEcCtD
Tretinoin—Diarrhoea—Etoposide—sarcoma	4.06e-05	0.000413	CcSEcCtD
Tretinoin—Eye disorder—Doxorubicin—sarcoma	4.05e-05	0.000412	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.05e-05	0.00265	CbGpPWpGaD
Tretinoin—Tinnitus—Doxorubicin—sarcoma	4.04e-05	0.000411	CcSEcCtD
Tretinoin—Flushing—Doxorubicin—sarcoma	4.02e-05	0.000409	CcSEcCtD
Tretinoin—Flatulence—Epirubicin—sarcoma	4.02e-05	0.000409	CcSEcCtD
Tretinoin—RXRA—Developmental Biology—EZR—sarcoma	4.02e-05	0.00263	CbGpPWpGaD
Tretinoin—Tension—Epirubicin—sarcoma	4e-05	0.000407	CcSEcCtD
Tretinoin—Nervousness—Epirubicin—sarcoma	3.96e-05	0.000403	CcSEcCtD
Tretinoin—Back pain—Epirubicin—sarcoma	3.94e-05	0.000401	CcSEcCtD
Tretinoin—Angiopathy—Doxorubicin—sarcoma	3.93e-05	0.0004	CcSEcCtD
Tretinoin—Dizziness—Etoposide—sarcoma	3.93e-05	0.000399	CcSEcCtD
Tretinoin—Chills—Doxorubicin—sarcoma	3.89e-05	0.000395	CcSEcCtD
Tretinoin—Arrhythmia—Doxorubicin—sarcoma	3.87e-05	0.000394	CcSEcCtD
Tretinoin—Vision blurred—Epirubicin—sarcoma	3.84e-05	0.000391	CcSEcCtD
Tretinoin—Alopecia—Doxorubicin—sarcoma	3.83e-05	0.000389	CcSEcCtD
Tretinoin—Mental disorder—Doxorubicin—sarcoma	3.8e-05	0.000386	CcSEcCtD
Tretinoin—Ill-defined disorder—Epirubicin—sarcoma	3.78e-05	0.000385	CcSEcCtD
Tretinoin—Vomiting—Etoposide—sarcoma	3.77e-05	0.000384	CcSEcCtD
Tretinoin—Erythema—Doxorubicin—sarcoma	3.77e-05	0.000384	CcSEcCtD
Tretinoin—Malnutrition—Doxorubicin—sarcoma	3.77e-05	0.000384	CcSEcCtD
Tretinoin—Anaemia—Epirubicin—sarcoma	3.77e-05	0.000383	CcSEcCtD
Tretinoin—Agitation—Epirubicin—sarcoma	3.75e-05	0.000381	CcSEcCtD
Tretinoin—Rash—Etoposide—sarcoma	3.74e-05	0.000381	CcSEcCtD
Tretinoin—Dermatitis—Etoposide—sarcoma	3.74e-05	0.00038	CcSEcCtD
Tretinoin—Headache—Etoposide—sarcoma	3.72e-05	0.000378	CcSEcCtD
Tretinoin—Flatulence—Doxorubicin—sarcoma	3.72e-05	0.000378	CcSEcCtD
Tretinoin—Tension—Doxorubicin—sarcoma	3.7e-05	0.000376	CcSEcCtD
Tretinoin—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—sarcoma	3.68e-05	0.00241	CbGpPWpGaD
Tretinoin—Malaise—Epirubicin—sarcoma	3.68e-05	0.000374	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.68e-05	0.00241	CbGpPWpGaD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.67e-05	0.0024	CbGpPWpGaD
Tretinoin—Nervousness—Doxorubicin—sarcoma	3.66e-05	0.000373	CcSEcCtD
Tretinoin—Syncope—Epirubicin—sarcoma	3.66e-05	0.000372	CcSEcCtD
Tretinoin—Back pain—Doxorubicin—sarcoma	3.65e-05	0.000371	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.64e-05	0.00239	CbGpPWpGaD
Tretinoin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	3.61e-05	0.00237	CbGpPWpGaD
Tretinoin—Palpitations—Epirubicin—sarcoma	3.6e-05	0.000366	CcSEcCtD
Tretinoin—CRABP2—Metabolism—ENO2—sarcoma	3.59e-05	0.00235	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—ENO2—sarcoma	3.59e-05	0.00235	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—ENO2—sarcoma	3.59e-05	0.00235	CbGpPWpGaD
Tretinoin—Loss of consciousness—Epirubicin—sarcoma	3.58e-05	0.000364	CcSEcCtD
Tretinoin—CRABP1—Metabolism—HBA1—sarcoma	3.56e-05	0.00233	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—HBA1—sarcoma	3.56e-05	0.00233	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—HBA1—sarcoma	3.56e-05	0.00233	CbGpPWpGaD
Tretinoin—Cough—Epirubicin—sarcoma	3.56e-05	0.000362	CcSEcCtD
Tretinoin—Vision blurred—Doxorubicin—sarcoma	3.56e-05	0.000362	CcSEcCtD
Tretinoin—Convulsion—Epirubicin—sarcoma	3.53e-05	0.000359	CcSEcCtD
Tretinoin—Nausea—Etoposide—sarcoma	3.53e-05	0.000359	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.53e-05	0.00231	CbGpPWpGaD
Tretinoin—Hypertension—Epirubicin—sarcoma	3.52e-05	0.000358	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.52e-05	0.0023	CbGpPWpGaD
Tretinoin—Ill-defined disorder—Doxorubicin—sarcoma	3.5e-05	0.000356	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.49e-05	0.00229	CbGpPWpGaD
Tretinoin—Anaemia—Doxorubicin—sarcoma	3.49e-05	0.000355	CcSEcCtD
Tretinoin—Arthralgia—Epirubicin—sarcoma	3.47e-05	0.000353	CcSEcCtD
Tretinoin—Myalgia—Epirubicin—sarcoma	3.47e-05	0.000353	CcSEcCtD
Tretinoin—Chest pain—Epirubicin—sarcoma	3.47e-05	0.000353	CcSEcCtD
Tretinoin—RXRA—Adipogenesis—CREB1—sarcoma	3.47e-05	0.00227	CbGpPWpGaD
Tretinoin—Agitation—Doxorubicin—sarcoma	3.47e-05	0.000353	CcSEcCtD
Tretinoin—Anxiety—Epirubicin—sarcoma	3.46e-05	0.000352	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	3.45e-05	0.00226	CbGpPWpGaD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	3.45e-05	0.000351	CcSEcCtD
Tretinoin—Discomfort—Epirubicin—sarcoma	3.43e-05	0.000349	CcSEcCtD
Tretinoin—Malaise—Doxorubicin—sarcoma	3.4e-05	0.000346	CcSEcCtD
Tretinoin—Dry mouth—Epirubicin—sarcoma	3.4e-05	0.000345	CcSEcCtD
Tretinoin—Syncope—Doxorubicin—sarcoma	3.38e-05	0.000344	CcSEcCtD
Tretinoin—Confusional state—Epirubicin—sarcoma	3.36e-05	0.000341	CcSEcCtD
Tretinoin—Palpitations—Doxorubicin—sarcoma	3.33e-05	0.000339	CcSEcCtD
Tretinoin—Anaphylactic shock—Epirubicin—sarcoma	3.33e-05	0.000338	CcSEcCtD
Tretinoin—Oedema—Epirubicin—sarcoma	3.33e-05	0.000338	CcSEcCtD
Tretinoin—Loss of consciousness—Doxorubicin—sarcoma	3.32e-05	0.000337	CcSEcCtD
Tretinoin—CYP2A6—Fluoropyrimidine Activity—TP53—sarcoma	3.31e-05	0.00217	CbGpPWpGaD
Tretinoin—Infection—Epirubicin—sarcoma	3.31e-05	0.000336	CcSEcCtD
Tretinoin—CYP1A1—Tryptophan metabolism—MDM2—sarcoma	3.3e-05	0.00216	CbGpPWpGaD
Tretinoin—Cough—Doxorubicin—sarcoma	3.29e-05	0.000335	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.29e-05	0.00216	CbGpPWpGaD
Tretinoin—Shock—Epirubicin—sarcoma	3.27e-05	0.000333	CcSEcCtD
Tretinoin—RXRA—Developmental Biology—MYOD1—sarcoma	3.27e-05	0.00214	CbGpPWpGaD
Tretinoin—Convulsion—Doxorubicin—sarcoma	3.27e-05	0.000332	CcSEcCtD
Tretinoin—Nervous system disorder—Epirubicin—sarcoma	3.26e-05	0.000332	CcSEcCtD
Tretinoin—Thrombocytopenia—Epirubicin—sarcoma	3.26e-05	0.000331	CcSEcCtD
Tretinoin—Hypertension—Doxorubicin—sarcoma	3.26e-05	0.000331	CcSEcCtD
Tretinoin—Tachycardia—Epirubicin—sarcoma	3.25e-05	0.00033	CcSEcCtD
Tretinoin—Skin disorder—Epirubicin—sarcoma	3.23e-05	0.000329	CcSEcCtD
Tretinoin—Hyperhidrosis—Epirubicin—sarcoma	3.22e-05	0.000327	CcSEcCtD
Tretinoin—Myalgia—Doxorubicin—sarcoma	3.21e-05	0.000327	CcSEcCtD
Tretinoin—Arthralgia—Doxorubicin—sarcoma	3.21e-05	0.000327	CcSEcCtD
Tretinoin—Chest pain—Doxorubicin—sarcoma	3.21e-05	0.000327	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.21e-05	0.0021	CbGpPWpGaD
Tretinoin—Anxiety—Doxorubicin—sarcoma	3.2e-05	0.000325	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	3.19e-05	0.000324	CcSEcCtD
Tretinoin—RXRA—Organelle biogenesis and maintenance—CREB1—sarcoma	3.18e-05	0.00208	CbGpPWpGaD
Tretinoin—Discomfort—Doxorubicin—sarcoma	3.17e-05	0.000323	CcSEcCtD
Tretinoin—Anorexia—Epirubicin—sarcoma	3.17e-05	0.000323	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.16e-05	0.00207	CbGpPWpGaD
Tretinoin—Dry mouth—Doxorubicin—sarcoma	3.14e-05	0.000319	CcSEcCtD
Tretinoin—Hypotension—Epirubicin—sarcoma	3.11e-05	0.000316	CcSEcCtD
Tretinoin—Confusional state—Doxorubicin—sarcoma	3.1e-05	0.000316	CcSEcCtD
Tretinoin—Anaphylactic shock—Doxorubicin—sarcoma	3.08e-05	0.000313	CcSEcCtD
Tretinoin—Oedema—Doxorubicin—sarcoma	3.08e-05	0.000313	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.07e-05	0.00201	CbGpPWpGaD
Tretinoin—Infection—Doxorubicin—sarcoma	3.06e-05	0.000311	CcSEcCtD
Tretinoin—ALDH1A1—Metabolism—PLCG1—sarcoma	3.04e-05	0.00199	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—PLCG1—sarcoma	3.04e-05	0.00199	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—PLCG1—sarcoma	3.04e-05	0.00199	CbGpPWpGaD
Tretinoin—Musculoskeletal discomfort—Epirubicin—sarcoma	3.03e-05	0.000308	CcSEcCtD
Tretinoin—Shock—Doxorubicin—sarcoma	3.03e-05	0.000308	CcSEcCtD
Tretinoin—Nervous system disorder—Doxorubicin—sarcoma	3.02e-05	0.000307	CcSEcCtD
Tretinoin—Thrombocytopenia—Doxorubicin—sarcoma	3.01e-05	0.000307	CcSEcCtD
Tretinoin—Insomnia—Epirubicin—sarcoma	3.01e-05	0.000306	CcSEcCtD
Tretinoin—Tachycardia—Doxorubicin—sarcoma	3.01e-05	0.000306	CcSEcCtD
Tretinoin—Skin disorder—Doxorubicin—sarcoma	2.99e-05	0.000304	CcSEcCtD
Tretinoin—Paraesthesia—Epirubicin—sarcoma	2.99e-05	0.000304	CcSEcCtD
Tretinoin—Hyperhidrosis—Doxorubicin—sarcoma	2.98e-05	0.000303	CcSEcCtD
Tretinoin—Dyspnoea—Epirubicin—sarcoma	2.97e-05	0.000302	CcSEcCtD
Tretinoin—Somnolence—Epirubicin—sarcoma	2.96e-05	0.000301	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.95e-05	0.00193	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	2.95e-05	0.00193	CbGpPWpGaD
Tretinoin—Anorexia—Doxorubicin—sarcoma	2.94e-05	0.000298	CcSEcCtD
Tretinoin—Dyspepsia—Epirubicin—sarcoma	2.93e-05	0.000298	CcSEcCtD
Tretinoin—Decreased appetite—Epirubicin—sarcoma	2.89e-05	0.000294	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.88e-05	0.00189	CbGpPWpGaD
Tretinoin—Hypotension—Doxorubicin—sarcoma	2.88e-05	0.000293	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Epirubicin—sarcoma	2.87e-05	0.000292	CcSEcCtD
Tretinoin—Fatigue—Epirubicin—sarcoma	2.87e-05	0.000292	CcSEcCtD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	2.87e-05	0.00188	CbGpPWpGaD
Tretinoin—Pain—Epirubicin—sarcoma	2.85e-05	0.000289	CcSEcCtD
Tretinoin—Constipation—Epirubicin—sarcoma	2.85e-05	0.000289	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.83e-05	0.00185	CbGpPWpGaD
Tretinoin—Musculoskeletal discomfort—Doxorubicin—sarcoma	2.81e-05	0.000285	CcSEcCtD
Tretinoin—Insomnia—Doxorubicin—sarcoma	2.79e-05	0.000283	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.77e-05	0.00181	CbGpPWpGaD
Tretinoin—Paraesthesia—Doxorubicin—sarcoma	2.77e-05	0.000281	CcSEcCtD
Tretinoin—Dyspnoea—Doxorubicin—sarcoma	2.75e-05	0.000279	CcSEcCtD
Tretinoin—Feeling abnormal—Epirubicin—sarcoma	2.74e-05	0.000279	CcSEcCtD
Tretinoin—Somnolence—Doxorubicin—sarcoma	2.74e-05	0.000278	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.73e-05	0.00179	CbGpPWpGaD
Tretinoin—Gastrointestinal pain—Epirubicin—sarcoma	2.72e-05	0.000277	CcSEcCtD
Tretinoin—Dyspepsia—Doxorubicin—sarcoma	2.71e-05	0.000276	CcSEcCtD
Tretinoin—RXRA—Gene Expression—FUS—sarcoma	2.71e-05	0.00178	CbGpPWpGaD
Tretinoin—Decreased appetite—Doxorubicin—sarcoma	2.68e-05	0.000272	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Doxorubicin—sarcoma	2.66e-05	0.00027	CcSEcCtD
Tretinoin—Fatigue—Doxorubicin—sarcoma	2.65e-05	0.00027	CcSEcCtD
Tretinoin—Urticaria—Epirubicin—sarcoma	2.64e-05	0.000269	CcSEcCtD
Tretinoin—Pain—Doxorubicin—sarcoma	2.63e-05	0.000268	CcSEcCtD
Tretinoin—Constipation—Doxorubicin—sarcoma	2.63e-05	0.000268	CcSEcCtD
Tretinoin—Body temperature increased—Epirubicin—sarcoma	2.63e-05	0.000267	CcSEcCtD
Tretinoin—Abdominal pain—Epirubicin—sarcoma	2.63e-05	0.000267	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.61e-05	0.00171	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—SRC—sarcoma	2.57e-05	0.00168	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	2.57e-05	0.00168	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	2.55e-05	0.00167	CbGpPWpGaD
Tretinoin—Feeling abnormal—Doxorubicin—sarcoma	2.54e-05	0.000258	CcSEcCtD
Tretinoin—Gastrointestinal pain—Doxorubicin—sarcoma	2.52e-05	0.000256	CcSEcCtD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	2.5e-05	0.00164	CbGpPWpGaD
Tretinoin—RXRA—Adipogenesis—CTNNB1—sarcoma	2.48e-05	0.00162	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	2.47e-05	0.00162	CbGpPWpGaD
Tretinoin—Hypersensitivity—Epirubicin—sarcoma	2.45e-05	0.000249	CcSEcCtD
Tretinoin—Urticaria—Doxorubicin—sarcoma	2.45e-05	0.000249	CcSEcCtD
Tretinoin—Body temperature increased—Doxorubicin—sarcoma	2.43e-05	0.000247	CcSEcCtD
Tretinoin—Abdominal pain—Doxorubicin—sarcoma	2.43e-05	0.000247	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.42e-05	0.00159	CbGpPWpGaD
Tretinoin—Asthenia—Epirubicin—sarcoma	2.39e-05	0.000243	CcSEcCtD
Tretinoin—RXRA—Developmental Biology—PTPRC—sarcoma	2.37e-05	0.00155	CbGpPWpGaD
Tretinoin—Pruritus—Epirubicin—sarcoma	2.35e-05	0.000239	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.32e-05	0.00152	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—PLCG1—sarcoma	2.32e-05	0.00152	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—MYC—sarcoma	2.3e-05	0.00151	CbGpPWpGaD
Tretinoin—Diarrhoea—Epirubicin—sarcoma	2.28e-05	0.000231	CcSEcCtD
Tretinoin—Hypersensitivity—Doxorubicin—sarcoma	2.27e-05	0.000231	CcSEcCtD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	2.25e-05	0.00148	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	2.25e-05	0.00148	CbGpPWpGaD
Tretinoin—Asthenia—Doxorubicin—sarcoma	2.21e-05	0.000225	CcSEcCtD
Tretinoin—Dizziness—Epirubicin—sarcoma	2.2e-05	0.000224	CcSEcCtD
Tretinoin—Pruritus—Doxorubicin—sarcoma	2.18e-05	0.000221	CcSEcCtD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	2.13e-05	0.00139	CbGpPWpGaD
Tretinoin—Vomiting—Epirubicin—sarcoma	2.12e-05	0.000215	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.11e-05	0.00138	CbGpPWpGaD
Tretinoin—Diarrhoea—Doxorubicin—sarcoma	2.11e-05	0.000214	CcSEcCtD
Tretinoin—Rash—Epirubicin—sarcoma	2.1e-05	0.000213	CcSEcCtD
Tretinoin—Dermatitis—Epirubicin—sarcoma	2.1e-05	0.000213	CcSEcCtD
Tretinoin—Headache—Epirubicin—sarcoma	2.08e-05	0.000212	CcSEcCtD
Tretinoin—Dizziness—Doxorubicin—sarcoma	2.04e-05	0.000207	CcSEcCtD
Tretinoin—NR0B1—Generic Transcription Pathway—MYC—sarcoma	2.03e-05	0.00133	CbGpPWpGaD
Tretinoin—Nausea—Epirubicin—sarcoma	1.98e-05	0.000201	CcSEcCtD
Tretinoin—Vomiting—Doxorubicin—sarcoma	1.96e-05	0.000199	CcSEcCtD
Tretinoin—Rash—Doxorubicin—sarcoma	1.94e-05	0.000197	CcSEcCtD
Tretinoin—Dermatitis—Doxorubicin—sarcoma	1.94e-05	0.000197	CcSEcCtD
Tretinoin—Headache—Doxorubicin—sarcoma	1.93e-05	0.000196	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.84e-05	0.0012	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.83e-05	0.0012	CbGpPWpGaD
Tretinoin—Nausea—Doxorubicin—sarcoma	1.83e-05	0.000186	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.82e-05	0.00119	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	1.81e-05	0.00118	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.64e-05	0.00108	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—FOXO1—sarcoma	1.64e-05	0.00108	CbGpPWpGaD
Tretinoin—RARG—Generic Transcription Pathway—MYC—sarcoma	1.63e-05	0.00107	CbGpPWpGaD
Tretinoin—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	1.62e-05	0.00106	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.6e-05	0.00105	CbGpPWpGaD
Tretinoin—RXRG—Generic Transcription Pathway—MYC—sarcoma	1.49e-05	0.000979	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.47e-05	0.000965	CbGpPWpGaD
Tretinoin—RARB—Generic Transcription Pathway—MYC—sarcoma	1.47e-05	0.00096	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.44e-05	0.000944	CbGpPWpGaD
Tretinoin—RARA—Generic Transcription Pathway—MYC—sarcoma	1.4e-05	0.00092	CbGpPWpGaD
Tretinoin—RXRB—Generic Transcription Pathway—MYC—sarcoma	1.4e-05	0.00092	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—ENO2—sarcoma	1.37e-05	0.000897	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.36e-05	0.000892	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—HBA1—sarcoma	1.36e-05	0.000891	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—KDR—sarcoma	1.36e-05	0.00089	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.21e-05	0.000793	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—ENO2—sarcoma	1.2e-05	0.000784	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—CREB1—sarcoma	1.19e-05	0.000781	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—HBA1—sarcoma	1.19e-05	0.000779	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PLCG1—sarcoma	1.16e-05	0.000761	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MMP2—sarcoma	1.11e-05	0.000727	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—ENO2—sarcoma	1.09e-05	0.000711	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—HBA1—sarcoma	1.08e-05	0.000707	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PLCG1—sarcoma	1.02e-05	0.000665	CbGpPWpGaD
Tretinoin—NR0B1—Gene Expression—MYC—sarcoma	9.76e-06	0.000639	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PLCG1—sarcoma	9.21e-06	0.000603	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—CTNNB1—sarcoma	8.51e-06	0.000557	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—ENO2—sarcoma	7.95e-06	0.000521	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—HBA1—sarcoma	7.9e-06	0.000518	CbGpPWpGaD
Tretinoin—RARG—Gene Expression—MYC—sarcoma	7.86e-06	0.000515	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—SRC—sarcoma	7.69e-06	0.000504	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—VEGFA—sarcoma	7.49e-06	0.000491	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—NRAS—sarcoma	7.4e-06	0.000485	CbGpPWpGaD
Tretinoin—RXRA—Generic Transcription Pathway—MYC—sarcoma	7.32e-06	0.00048	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—ENO2—sarcoma	7.29e-06	0.000478	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—HBA1—sarcoma	7.25e-06	0.000475	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—MYC—sarcoma	7.19e-06	0.000471	CbGpPWpGaD
Tretinoin—RARB—Gene Expression—MYC—sarcoma	7.05e-06	0.000462	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—MYC—sarcoma	6.76e-06	0.000443	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—MYC—sarcoma	6.76e-06	0.000443	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PLCG1—sarcoma	6.75e-06	0.000442	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—EGFR—sarcoma	6.74e-06	0.000441	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—KRAS—sarcoma	6.37e-06	0.000417	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PLCG1—sarcoma	6.19e-06	0.000405	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—ENO2—sarcoma	5.88e-06	0.000385	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—HBA1—sarcoma	5.85e-06	0.000383	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—ENO2—sarcoma	5.75e-06	0.000377	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—HBA1—sarcoma	5.71e-06	0.000374	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—ENO2—sarcoma	5.43e-06	0.000356	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—HRAS—sarcoma	5.41e-06	0.000354	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—HBA1—sarcoma	5.4e-06	0.000354	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PLCG1—sarcoma	4.99e-06	0.000327	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—ENO2—sarcoma	4.98e-06	0.000326	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—HBA1—sarcoma	4.95e-06	0.000324	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PLCG1—sarcoma	4.88e-06	0.00032	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PLCG1—sarcoma	4.61e-06	0.000302	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PLCG1—sarcoma	4.23e-06	0.000277	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—ENO2—sarcoma	4.05e-06	0.000266	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—HBA1—sarcoma	4.03e-06	0.000264	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—MYC—sarcoma	3.52e-06	0.000231	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PLCG1—sarcoma	3.44e-06	0.000225	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—ENO2—sarcoma	2.67e-06	0.000175	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—HBA1—sarcoma	2.66e-06	0.000174	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PLCG1—sarcoma	2.27e-06	0.000149	CbGpPWpGaD
